Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The results from an innovative, “virtual” clinical trial were presented at the 2019 ASCO Annual Meeting.
As an eligibility barrier cracks, a lung cancer patient gets a new lease on life.
This summer I am bouncing, and though I am not posting stuff, I am still writing and looking for my voice and how I want my own story to go.
“The bladder cancer research community pulled together to get this trial done,” says principal investigator Thomas Flaig, MD.
Even positive breaking news looks different to people who know the reality of a hard-to-treat cancer.
Researchers are interested in combining PARP inhibitors with immunotherapies for pancreatic and other cancers with defects in DNA repair.
T\ogether, these trials indicate that triple combos show promise and while there are significant toxicities, they are mostly manageable.
A new type of immunotherapy shows promising activity against cancers caused by human papillomavirus (HPV).
A long and successful battle with melanoma has left Dan Engel a new and different man.
Why the head of the world’s largest cancer organization braved dirt roads and crowded urban streets to reach impoverished cancer centers
Results of a study indicate that these trials can be good therapeutic options for people with heavily pretreated ovarian cancer.
Keytruda and Imfinzi showed response rates and safety profiles similar to those seen in HIV-negative people.
ASCO and Friends of Cancer Research proposed new eligibility guidelines in 2017.
Nine organizations join forces to make clinical trial information available, paving the way for improved patient matching.
Eighty percent of medications that receive accelerated approval don’t extend overall survival.
More patients with metastatic cancer and bone metastases are living longer today, so the need to address bone pain has increased.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.